Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

August 9, 2022

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

July 28, 2022

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

July 22, 2022

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 19, 2022

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

July 19, 2022

Revolution Medicines Announces Commencement of Public Offering of Common Stock

July 13, 2022

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

June 28, 2022

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

June 9, 2022

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

May 9, 2022

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

April 21, 2022

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 1 - 10 of 87

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2022 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations